摘要
目的观察2型糖尿病以二甲双胍+利格列汀治疗的效果。方法选取2021年6月—2023年3月沂水县诸葛镇中心卫生院收治的86例2型糖尿病患者为研究对象,采用随机数表法分为两组,各43例。观察组实施二甲双胍+利格列汀治疗,对照组实施二甲双胍治疗,对比两组患者血糖指标(空腹血糖与餐后2 h血糖)、血脂水平[(总胆固醇(total cholesterol,TC)、三酰甘油(triacylglycerol,TG)、高密度脂蛋白(high density lipo⁃protein,HDL-C)、低密度脂蛋白(low density lipoprotein,LDL-C)]、不良反应发生情况。结果治疗后,观察组血糖、血脂水平均优于对照组,差异有统计学意义(P<0.05)。观察组用药期间的不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论二甲双胍+利格列汀的治疗方案能够促使2型糖尿病患者的血糖更加稳定,延缓疾病的发展。
Objective To observe the effect of metformin+linagliptin on type 2 diabetes treatment.Methods A total of 86 patients with type 2 diabetes who were admitted to Zhuge Town Central Health Center in Yishui County from June 2021 to March 2023 were selected as the study subjects,and they were divided into two groups with 43 cases in each group by random number table method.The observation group was treated with metformin+linagliptin,and the control group was treated with metformin,and the blood glucose indexes(fasting blood glucose and 2-hour postpran-dial blood glucose),blood lipid levels[(total cholesterol(TC),triacylglycerol(TG),high density lipoprotein(HDL-C),and low density lipoprotein(LDL-C)],and the occurrence of adverse reactions were compared between the two groups.Results After treatment,the blood glucose and lipid levels of the observation group were better than those of the con-trol group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the obser-vation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The treatment regimen of metformin+linagliptin can promote more stable blood sugar in patients with type 2 diabetes and delay the progression of the disease.
作者
王洪利
WANG Hongli(Yishui County Zhuge Town Central Health Center,Linyi,Shandong Province,276000 China)
出处
《糖尿病新世界》
2023年第21期100-102,106,共4页
Diabetes New World Magazine
关键词
2型糖尿病
利格列汀
二甲双胍
复合用药
Type 2 diabetes mellitus
Linagliptin
Metformin
Combination medication
